Compare ESLT & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESLT | ONC |
|---|---|---|
| Founded | 1966 | 2010 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9B | 34.8B |
| IPO Year | 1996 | N/A |
| Metric | ESLT | ONC |
|---|---|---|
| Price | $685.78 | $346.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $550.33 | $369.50 |
| AVG Volume (30 Days) | 131.8K | ★ 304.0K |
| Earning Date | 03-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ 68.63 | N/A |
| EPS | ★ 9.87 | 0.58 |
| Revenue | ★ $7,720,284,000.00 | $4,972,687,000.00 |
| Revenue This Year | $18.47 | $895.40 |
| Revenue Next Year | $10.93 | $22.04 |
| P/E Ratio | ★ $72.98 | $592.40 |
| Revenue Growth | 18.35 | ★ 50.43 |
| 52 Week Low | $294.99 | $196.45 |
| 52 Week High | $740.67 | $385.22 |
| Indicator | ESLT | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 58.63 |
| Support Level | $690.00 | $328.91 |
| Resistance Level | $721.76 | $353.00 |
| Average True Range (ATR) | 22.06 | 9.40 |
| MACD | -9.46 | 0.45 |
| Stochastic Oscillator | 6.60 | 75.30 |
Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.